Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.
To evaluate the in vitro efficacy of common antifungal drugs, as well as the interactions of caspofungin with voriconazole, amphotericin B, or itraconazole against the pathogenic black yeast Exophiala dermatitidis from China, the minimal inhibitory concentrations (MICs) of terbinafine, voriconazole, itraconazole, amphotericin B, fluconazole, and caspofungin against 16 strains of E. dermatitidis were determined by using CLSI broth microdilution method (M38-A2). The minimal fungicidal concentrations (MFCs) were also determined. Additionally, the interactions of caspofungin with voriconazole, amphotericin B, itraconazole or fluconazole, that of terbinafine with itraconazole, or that of fluconazole with amphotericin B were assessed by using the checkerboard technique. The fractional inhibitory concentration index (FICI) was used to categorize drug interactions as following, synergy, FICI ≤ 0.5; indifference, FICI > 0.5 and ≤4.0; or antagonism, FICI > 4.0. The MIC ranges of terbinafine, voriconazole, itraconazole, amphotericin B, fluconazole, and caspofungin against E. dermatitidis were 0.06-0.125 mg/l, 0.25-1.0 mg/l, 1.0-2.0 mg/l, 1.0-2.0 mg/l, 16-64 mg/l, and 32-64 mg/l, respectively. The in vitro interactions of caspofungin with voriconazole, amphotericin B, and itraconazole showed synergic effect against 10/16(62.5%), 15/16(93.75%), and 16/16(100%) isolates, while that of caspofungin with fluconazole showed indifference. Besides, the interaction of terbinafine with itraconazole as well as that of fluconazole with amphotericin B showed indifference. Terbinafine, voriconazole, itraconazole, and amphotericin B have good activity against E. dermatitidis. The combinations of caspofungin with voriconazole, amphotericin B or itraconazole present synergic activity against E. dermatitidis. These results provide the basis for novel options in treating various E. dermatitidis infections.
Sun
Yi
Y
Department of Dermatology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, No. 8, Xishiku St., 100034, Beijing, People's Republic of China.
Liu
Wei
W
Wan
Zhe
Z
Wang
Xiaohong
X
Li
Ruoyu
R
D000935:Antifungal Agents / Q000494:pharmacology*; D002681:China; D004338:Drug Combinations; D004347:Drug Interactions; D005093:Exophiala / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D009181:Mycoses / Q000382:microbiology
D000935:Antifungal Agents; D004338:Drug Combinations
Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):575-6
12938012
Respiration. 2004 Jul-Aug;71(4):360-6
15316209
Expert Rev Anti Infect Ther. 2005 Aug;3(4):601-12
16107199
Mycoses. 1993 Jan-Feb;36(1-2):1-7
8316255
Ann Hematol. 2004 Jun;83(6):390-3
14666380
J Microbiol Methods. 2010 Feb;80(2):138-42
19961882
Med Mycol. 2009;47(6):653-7
19184769
Eur J Pediatr. 1992 May;151(5):344-6
1396889
Med Mycol. 2009 Feb;47(1):101-9
19107634
J Med Microbiol. 2009 Sep;58(Pt 9):1243-1246
19528179
Antimicrob Agents Chemother. 2009 Feb;53(2):788-90
19029317
J Clin Microbiol. 2002 Oct;40(10):3776-81
12354880
Antimicrob Agents Chemother. 2000 Feb;44(2):470-2
10639389
J Clin Microbiol. 2001 Mar;39(3):954-8
11230410
J Infect Dis. 2003 Jun 15;187(12):1834-43
12792859
J Clin Microbiol. 2004 Dec;42(12):5950-3
15583351
J Antimicrob Chemother. 2006 Dec;58(6):1168-76
17071635
J Child Neurol. 2009 Mar;24(3):342-5
19258294
J Infect. 2006 May;52(5):e133-7
16427702
J Antimicrob Chemother. 2003 Jul;52(1):1
12805255
Scand J Infect Dis. 2001;33(10):777-9
11728050
Expert Opin Pharmacother. 2009 Nov;10(16):2723-33
19874252
Clin Exp Dermatol. 2007 Sep;32(5):539-40
17524069
Can J Infect Dis Med Microbiol. 2008 Jan;19(1):55-62
19145263
Mycoses. 2000 Sep;43(7-8):309-12
11036402
J Am Acad Dermatol. 1983 Jan;8(1):1-16
6826791
Infection. 2007 Oct;35(5):364-6
17721739
Rev Iberoam Micol. 2009 Dec 31;26(4):223-7
19836985
Curr Opin Infect Dis. 2008 Dec;21(6):580-6
18978525
Cancer. 2003 Feb 15;97(4):1025-32
12569602
Mycopathologia. 1987 Sep;99(3):175-81
3657909
Respir Med. 2006 Nov;100(11):2069-71
16626952
Blood. 2005 Oct 15;106(8):2641-5
15998833
Lancet. 2003 Oct 4;362(9390):1142-51
14550704
J Antimicrob Chemother. 2009 Feb;63(2):340-2
19054803
Med Mycol. 2009 Feb;47(1):41-3
19107637
Rev Iberoam Micol. 2008 Jun;25(2):101-6
18473504
Lancet Infect Dis. 2009 Jun;9(6):376-83
19467477